恒瑞医药两款药物临床试验获批

Core Insights - Heng Rui Medicine has received clinical trial approval for two drugs, SHR-2173 and HRS-9821, from the National Medical Products Administration, indicating progress in its innovative drug development pipeline [1][2] Group 1: Drug Development - SHR-2173 is a self-developed biological product targeting abnormally activated immune cells, aimed at treating primary membranous nephropathy, with a total R&D investment of approximately 64.07 million yuan [1] - HRS-9821 is a small molecule PDE3/PDE4 inhibitor intended for the maintenance treatment of chronic obstructive pulmonary disease (COPD), with a total R&D investment of about 38.43 million yuan [1] - The global market for similar products includes Ensifentrine, which is expected to generate sales of approximately 42 million dollars in 2024 [1] Group 2: Company Strategy and Market Position - Heng Rui Medicine has been focusing on innovative R&D, having obtained approvals for 23 first-class innovative drugs and 4 second-class new drugs in China, with over 90 self-innovated products currently in clinical development [2] - The company has expanded its research into various therapeutic areas, including metabolism, cardiovascular diseases, immunology, respiratory diseases, and neuroscience [2] - Heng Rui Medicine's recent listing on the Hong Kong Stock Exchange marks a significant step in its internationalization strategy, enhancing its global brand influence and attracting foreign investment [3]